numares develops and markets products for clinical diagnostics and life science research. Medical and diagnostic tests with CE marking for the use in clinical practice, e.g. for diagnosis and therapy monitoring.
numares AG is headquartered in the Biopark Regensburg, Germany.
Since 2014, numares has been a Aktiengesellschaft.
The majority shareholder in numares AG is the SHS Gesellschaft für Beteiligungsmanagement in Tübingen, Germany.
The company was launched in April 2004 as a "spin-off" of the Institute of Biophysics at the University of Regensburg with a new method for the routine determination of lipoproteins using nuclear magnetic resonance spectroscopy (NMR).
Today, the focus is on the development of in vitro diagnostic tests and test systems for Clinical Diagnostics and Life Science Research, based on the use of complex metabolic data and numares' proprietary Magentic Group Signaling (MGS®) technology.
|2017||Launch of AXINON® renalTX-SCORE®-U100: first metabolomics IVD test for allograft rejection diagnostics after kidney transplantation|
|2017||Collaboration with Oxford University on the development of Multiple Sclerosis diagnostic test|
|2017||Launch of RUO test AXINON® insightLP-S50TM for lipoprotein composition analysis|
|2016||1,000.000 performed analyses|
|2016||numares completes another financing round|
|2015||Launch of CE-marked IVD tests AXINON® lipoFIT®-S100 and AXINON® lipoFIT®-S100-400 for NMR-based lipoprotein profiling|
|2014||600.000 performed analyses|
|2014||Successful completion of studies on kidney transplantation and prostate cancer|
|2014||numares GmbH becomes numares AG|
|2014||Cooperation with a german laboratory network: commissioning of a test system for lipoprotein profiling|
|2013||200.000 performed analyses|
|2013||Bulk order from a U.S. laboratory chain: installation of multiple test systems for lipoprotein profiling|
|2013||Successful certification of numares according to EN ISO 13485: 2012 as a manufacturer of in-vitro diagnostics (IVD)|
|2012||Expansion of technical capacity by 400 MHz and 600 MHz NMR-high throughput platform|
|2010||100.000 performed analyses|
|2009||Certification as per EN ISO 13485:2003|
|ab 2005||Measurements within large studies such as GRAPHIC and KORA|
|2004||First patent for the determination of lipoproteins in body fluids (lipoprotein profiling)|